A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry
Clinical trial NCT07335198 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07335198
- Sponsor
- GlaxoSmithKline
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-05
- Primary completion
- 2026-09-04
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.